Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway.

Authors:
Jochen Rutz Sebastian Maxeiner Eva Juengel Felix K-H Chun Igor Tsaur Roman A Blaheta

Nutrients 2022 Jan 15;14(2). Epub 2022 Jan 15.

Department of Urology, Goethe-University, 60590 Frankfurt am Main, Germany.

Bladder cancer patients whose tumors develop resistance to cisplatin-based chemotherapy often turn to natural, plant-derived products. Beneficial effects have been particularly ascribed to polyphenols, although their therapeutic relevance when resistance has developed is not clear. The present study evaluated the anti-tumor potential of polyphenol-rich olive mill wastewater (OMWW) on chemo-sensitive and cisplatin- and gemcitabine-resistant T24, RT112, and TCCSUP bladder cancer cells in vitro. The cells were treated with different dilutions of OMWW, and tumor growth and clone formation were evaluated. Possible mechanisms of action were investigated by evaluating cell cycle phases and cell cycle-regulating proteins. OMWW profoundly inhibited the growth and proliferation of chemo-sensitive as well as gemcitabine- and cisplatin-resistant bladder cancer cells. Depending on the cell line and on gemcitabine- or cisplatin-resistance, OMWW induced cell cycle arrest at different phases. These differing phase arrests were accompanied by differing alterations in the CDK-cyclin axis. Considerable suppression of the Akt-mTOR pathway by OMWW was observed in all three cell lines. Since OMWW blocks the cell cycle through the manipulation of the cyclin-CDK axis and the deactivation of Akt-mTOR signaling, OMWW could become relevant in supporting bladder cancer therapy.

Download full-text PDF

 Source
http://dx.doi.org/10.3390/nu14020369DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778865PMC
January 2022

Publication Analysis

Top Keywords

bladder cancer
20
cancer cells
12
cell cycle
12
cells vitro
8
mill wastewater
8
olive mill
8
growth proliferation
8
cisplatin- gemcitabine-resistant
8
omww
7
cell
6
bladder
5
cancer
5
cycle arrest
4
gemcitabine-resistant t24
4
induced cell
4
omww chemo-sensitive
4
t24 rt112
4
omww induced
4
rt112 tccsup
4
tccsup bladder
4

Keyword Occurance

Similar Publications

Domain adaptation of automated treatment planning from computed tomography to magnetic resonance.

Authors:
Aly Khalifa Jeff D Winter Inmaculada Navarro Chris McIntosh Thomas G Purdie

Phys Med Biol 2022 May 24. Epub 2022 May 24.

University Health Network, 610 University Avenue, Toronto, Ontario, M5G 2C4, CANADA.

Objective: Machine learning (ML) based radiation treatment (RT) planning addresses the iterative and time-consuming nature of conventional inverse planning. Given the rising importance of magnetic resonance (MR) based treatment planning workflows, we sought to determine if an ML based treatment planning model, trained on computed tomography (CT) imaging, could be applied to MR through domain adaptation.

Methods: In this study, MR and CT imaging was collected from 55 prostate cancer patients treated on an MR linear accelerator. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Effects of treatments on gender differences in patients with localized muscle-invasive bladder cancer.

Authors:
Wei Zhuang Haiyun Xie Shicheng Yu Yining Li Gonghui Li

Int Urol Nephrol 2022 May 24. Epub 2022 May 24.

Department of Urology, Sir Run Run Shaw Hospital, Medicine School of Zhejiang University, 3 Qingchun East Road, Shangcheng District, Hangzhou, 310016, Zhejiang, China.

Purpose: To explore the gender differences in survival under different treatments in localized muscle-invasive bladder cancer (MIBC), and to find clinical strategies to improve the poor prognosis of female with bladder cancer (BC).

Methods: Patients with localized MIBC were collected in the SEER database from 2010 to 2016 to analyze the gender differences in clinical characteristics. Propensity score matching was used to balance the effects of confounding factors. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Less Is More.

Authors:
Katherine E Saunders J Cody Craig Derek L Hoerres Susan J Maygarden Sara E Wobker

Am J Clin Pathol 2022 May 24. Epub 2022 May 24.

Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Objectives: Neoadjuvant chemotherapy (NAC) confers a survival advantage for muscle-invasive bladder cancer and is now recommended for chemotherapy-eligible patients. NAC may result in absent gross tumor, and current cystectomy gross examination protocols do not specify approach for these cases.

Methods: We included cystectomies performed from 2010 to 2018, capturing a period pre- and post-NAC recommendations. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Targeting alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial.

Authors:
Sumanta K Pal Diederik M Somford Petros Grivas Srikala S Sridhar Shilpa Gupta Joaquim Bellmunt Guru Sonpavde Mark T Fleming Seth P Lerner Yohann Loriot Jean Hoffman-Censits Begoña P Valderrama Corina Andresen Marco J Schnabel Suzanne Cole Siamak Daneshmand

Future Oncol 2022 May 24. Epub 2022 May 24.

Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.

PROOF 302 is an ongoing randomized, double-blind, placebo-controlled, adjuvant phase III trial (NCT04197986) in approximately 218 patients from 120 centers worldwide. Eligibility criteria include post-surgical high-risk muscle-invasive upper tract urothelial cancer (85% of patients) or urothelial bladder cancer (15%), susceptible alterations (activating mutations, gene fusions or rearrangements), ≤120 days following radical surgery and ineligible for/or refusing cisplatin-based (neo)adjuvant chemotherapy. Patients receive either oral infigratinib 125 mg or placebo daily on days 1-21 of a 28-day cycle for up to 52 weeks or until recurrence, unacceptable toxicity or death. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

A gender-related dichotomy in bladder cancer.

Authors:
Alessia Cimadamore Jeremy Y Teoh Ettore DI Trapani Wojciech Krajewski Wei Shen Tan Keiichiro Mori Francesco Del Giudice Diego M Carrion Marco Moschini

Minerva Urol Nephrol 2022 Jun;74(3):376-378

Unit of Urology, Division of Oncology (URI), IRCCS San Raffaele Hospital, Milan, Italy.

View Article and Full-Text PDF
June 2022
Similar Publications
}